Research Analysts Offer Predictions for ANIX FY2025 Earnings

Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 EPS estimates for shares of Anixa Biosciences in a report issued on Tuesday, June 3rd. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.38) per share for the year, up from their prior estimate of ($0.41). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences' FY2026 earnings at ($0.39) EPS.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01.

Other research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday. D. Boral Capital reiterated a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Thursday, May 29th. Finally, Maxim Group began coverage on shares of Anixa Biosciences in a research note on Friday, March 21st. They issued a "buy" rating and a $10.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $9.00.

Anixa Biosciences Price Performance

Anixa Biosciences stock traded down $0.08 during mid-day trading on Thursday, reaching $2.76. 80,922 shares of the company traded hands, compared to its average volume of 89,709. Anixa Biosciences has a fifty-two week low of $2.07 and a fifty-two week high of $4.20. The company has a market capitalization of $88.90 million, a price-to-earnings ratio of -7.08 and a beta of 0.34. The firm's fifty day moving average is $2.66 and its two-hundred day moving average is $2.79.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar acquired 10,000 shares of the business's stock in a transaction dated Wednesday, June 4th. The shares were purchased at an average price of $2.85 per share, for a total transaction of $28,500.00. Following the completion of the purchase, the chief executive officer now directly owns 569,925 shares of the company's stock, valued at $1,624,286.25. The trade was a 1.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 25.30% of the company's stock.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in ANIX. Focus Partners Wealth purchased a new stake in Anixa Biosciences during the fourth quarter worth $162,000. Jane Street Group LLC purchased a new stake in Anixa Biosciences during the fourth quarter worth $67,000. Prosperity Wealth Management Inc. purchased a new stake in Anixa Biosciences during the fourth quarter worth $54,000. Private Advisor Group LLC purchased a new stake in Anixa Biosciences during the first quarter worth $35,000. Finally, LPL Financial LLC boosted its holdings in Anixa Biosciences by 37.2% during the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after buying an additional 11,633 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.